MHRA Appoints New Chief Executive
News Jul 05, 2013
He will take up the post in September when current Chief Executive Sir Kent Woods steps down, after ten years with the agency.
Dr Hudson is currently the MHRA’s Licensing Director, responsible for the majority of medicines licensing activities. He is the UK delegate to the Committee on Human Medicinal Products (CHMP) at the European Medicines Agency and has been its vice-chairman since October 2012.
In line with Government protocol, the Department of Health officially announced the appointment and their press release is available through the link below.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019